u/kcn_alert

I wanted to share some changes coming to corneal crosslinking, a sight-saving procedure that treats progressive corneal warpage known as keratoconus.

Keratoconus is a progressive condition that usually starts in the late teens/early 20s. The cornea gradually warps, causing irregular astigmatism, blurred vision, and other problems. Patients typically need expensive hard contact lenses. Those with extreme warpage often need corneal transplantation, which then entails a long recovery period and a host of risks.

Enter crosslinking (CXL). This sight-saving procedure was developed almost 30 years ago. It gained FDA approval in 2016. CXL is a simple procedure where riboflavin is then applied to the cornea under UV light, strengthening the cornea and halting its warpage. When performed early enough in the disease course, it can prevent further progression and even prevent long-term vision loss.

A single company, Avedro, gained FDA approval of both the drug and the UV light device in 2016. Glaukos then bought Avedro. Over time, the cost of the procedure rose from a few hundred to about $5,000 per eye, with surgeons required to purchase riboflavin from the manufacturer in order to obtain a card that would activate the device. This meant you could not obtain compounded riboflavin to save costs.

Insurance coverage has been inconsistent, especially those on Medicaid, which is what most affected patients have when they need CXL.

In the existing "epi-off" CXL, the corneal epithelium is removed at the start of the procedure. Recently, Glaukos has obtained FDA approval for another version of CXL known as "epi-on," meaning the corneal epithelium is not removed. They are raising the price to about $78,000 per eye.

Yes, you heard that right.

Glaukos is also sunsetting its epi-off procedure (while claiming it will allow select patients to continue to access it through an application process). This renders the epi-off devices surgeons purchased largely useless. However, the two procedures are not equivalent; the data suggests epi-off offers advantages in longevity and efficacy over epi-off. A lot of ophthalmologists feel surgeons should be able to determine what's best for their patients and want both procedures to be readily available.

CXL routinely costs around $1,000 per eye in other countries. Many countries have access to a variety of procedures.

Glaukos obtained a Rare Disease Exemption from the FDA, though many of us in the ophthalmology world recognize that the prevalence of keratoconus is much higher than indicated in the outdated studies Glaukos used to pursue RDE status.

Glaukos states that it will use Patient Assistance Programs to ensure patients can access the procedure. But it's not yet clear how this will work for those on Medicaid, nor whether the Patient Access Program has a sunset date. And Glaukos will charge insurance these high rates, meaning the price Glaukos demands will indirectly trickle down to the rest of us. It is scary to think that corporate profits and complex insurance processes may preclude access and lead to preventable blindness.

There is additional concern over how Glaukos may be using CXL to promote optometric scope expansion. Epi-on CXL is arguably an "easier" and less invasive procedure to perform, and unlike epi-off, does not require documentation of disease progression, so it can be theoretically be performed by a wider array of practitioners. But I would argue that accurate diagnosis is still critical. For a time, Glaukos was cross-promoting a corneal topographer (imaging device) with an ectasia display - making it easier to "suspect" keratoconus - but I am of the opinion that this was intended to water down the diagnostic process. Keratoconus can really only be diagnosed by the more-complex tomogrpahy, which requires more skill to interpret.

Ophthalmologists now fear a return to the pre-crosslinking times, where people would routinely go blind from keratoconus. We are concerned that patients will not have ready access to this sight-saving procedure due to the costs and the quirks of insurance, and we are concerned that people will go blind as a result. We are concerned about patients not having access to epi-off crosslinking even if their surgeon determines that they need it.

As a publicly-traded company that has spent money on the R&D to get epi-on CXL FDA-approved, Glaukos is entitled to turn a profit. That is not in question. They are not a non-profit organization. However, the heavy-handed methods they are employing (sunsetting epi-off; raising the price; controlling access to both drug and device) that risk preventing patients from accessing CXL are what is concerning.

Glaukos has been on a PR blitz about this, with numerous articles in ophthalmic journals and posts on physician forums written by their physician consultants supporting the benefits of CXL and praising their patient access efforts. But the devil is in the details, and I am extremely concerned about patient access to this sight-saving procedure now and in the long-term.